AstraZeneca's Alexion Pharmaceuticals was sued in Massachusetts federal court on Wednesday in a class action complaint ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p14,200.00. The ...

AstraZeneca Pharmaceuticals LP and a Christian sales specialist have agreed to settle his suit over the company’s failure to ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...

The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts ...

Biopharmaceutical multinational AstraZeneca is not letting a bumpy 2024 dictate its path forward in China, and in the wake of a recent controversy emerges a multibillion-dollar commitment to China ...

AstraZeneca is making a $1bn investment for the long term, but what lies in store for investors over the next 12 months? Here are the latest forecasts. When investing, your capital is at risk. The ...

AstraZeneca anticipates that the expansion will increase its workforce in the region to 1,700. Credit: Robert Way/Shutterstock. AstraZeneca has announced a $2.5bn investment in the company’s sixth ...

The investments come amid an ongoing insurance fraud probe into AstraZeneca’s former China head Leon Wang—and despite mounting pressure from President Trump for pharma companies to re-shore their ...

Following a decline in GBS cases, PMC has written to the state public health department on Thursday to declare end of the rare nerve disorder outbreak Pune: Following a decline in Guillain-Barré ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer (NSCLC), the British pharma has rolled out early data from a trial ...